Updates are available Correction dated 2024-07-02
Click to view Correction: https://doi.org/10.1038/s41591-024-03161-w
-
Authors
Saba, Nabil F. http://orcid.org/0000-0003-4972-1477
Steuer, Conor E.
Ekpenyong, Asari http://orcid.org/0000-0002-8515-1304
McCook-Veal, Ashley http://orcid.org/0000-0001-5368-4977
Magliocca, Kelly
Patel, Mihir
Schmitt, Nicole C. http://orcid.org/0000-0002-0571-3531
Stokes, William http://orcid.org/0000-0002-1616-7046
Bates, James E.
Rudra, Soumon
Remick, Jill
McDonald, Mark http://orcid.org/0000-0003-3021-9356
Abousaud, Marin
Tan, Aik Choon
Fadlullah, Muhammad Zaki Hidayatullah
Chaudhary, Ritu
Muzaffar, Jameel
Kirtane, Kedar
Liu, Yuan
Chen, Georgia Z.
Shin, Dong M.
Teng, Yong
Chung, Christine H. http://orcid.org/0000-0001-5199-4306
-
Funding
Funding for this research was provided by:
Exelixis (WCI4234)
Emory University | Winship Cancer Institute (P30CA138292)
U.S. Department of Health & Human Services | NIH | National Institute of Dental and Craniofacial Research (R01DE028351)
Huntsman Cancer Institute (1S10OD021644-01A1, 1S10OD021644-01A1)
- License Information
-
More Information
Article History
Received: 6 July 2022
Accepted: 24 February 2023
First Online: 3 April 2023
Change Date: 2 July 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41591-024-03161-w
Competing interests
: N.F.S. reports advisory roles for Merck, AZ, Eisai, Exelixis, Vaccinex, BNT and CUE. J.E.B. reports advisory roles for Galera Therapeutics and Castle Biosciences. N.C.S. reports research funding from Astex. C.H.C. reports advisory board participation for Merck, Exelixis, Fulgent, Genmab and Brooklyn ImmunoTherapeutics. The other authors declare no competing interests.
